Issue is we in limbo between a P/E multiple company that is deep in clinical development with a partnership structure that is messy.... Was great at the time but makes a t/o less likely IMHO short term and the chances of a double swallow with Acadia is unlikely, would be a negotiation nightmare. The P3-FDA endpoint limbo is also a miss by the company, should have been discussed, put and tucked into bed with FDA before the last announcement. Also the pie in the sky T/O $40-100 are a dream. We ain't the DAQ, we don't get valued like that and DCF broker valuations don't really matter when the market (although SP is manipulated) has us sitting at $12. Every potential purchaser that is listed has a obligation to not pay overs for a company (regardless of "worth") and we are trading no where near what we should be. So maybe $25 is where we land VLA style.
NEU Price at posting:
$12.28 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)